You wouldn't want to be holding the bag if it does. Considering these were trading at .006c before acq announcement. Paying 1.2c would certainly be a premium
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%